Safety and efficacy results of the Phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations

Silevertinib is a brain-penetrant therapeutic option designed to target a wide range of non-classical EGFR mutations in non-small cell lung cancer. In its Phase 2 evaluation for first-line treatment, the drug demonstrated meaningful systemic tumor reduction and notable central nervous system activity for individuals presenting with brain metastases. The treatment carries a safety profile typical of its drug class, with side effects that remain manageable through supportive care interventions and strategic dose modifications.